Essex Bio-Technology Limited has announced the completion of the last patient visit in an international multi-centre phase 3 clinical study for HLX04-O, a bio-pharmaceutical product designed for the treatment of wet age-related macular degeneration (wet-AMD). This pivotal study aims to compare the efficacy and safety of HLX04-O with ranibizumab, a standard treatment for wet-AMD. The completion of this study marks a significant step towards addressing the unmet need in the Chinese market, where no bevacizumab product for wet-AMD is currently approved.
Essex Bio-Technology Limited is a biopharmaceutical company that specializes in the development of innovative treatments, particularly in the field of ophthalmology. The company collaborates with partners, including Shanghai Henlius Biotech, Inc., to co-develop bio-pharmaceutical products such as anti-VEGF drugs for treating conditions like exudative (wet) age-related macular degeneration.
This development is crucial for patients suffering from wet-AMD, a leading cause of vision loss among the elderly, offering hope for a new treatment option that could potentially improve the quality of life for many.
